Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy

Psychiatria Polska

Volumn 48, Issue 1, 2014, Pages 49-58

  Gosek, Paweł ^a   Chojnacka, Magdalena ^a   Bieńkowski, Przemysław ^b   Świecicki, Łukasz ^a  

^a II Klinika Psychiatrcyzna IPiN   (Poland)

^b Department of Nervous System Pharmacology and Physiology IPiN ^*  (Poland)

Author keywords

Depression; Ketamine; Treatment

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMISULPRIDE; AMITRIPTYLINE; ANALGESIC AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; KETAMINE; LAMOTRIGINE; LITHIUM; MIANSERIN; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; QUETIAPINE; REBOXETINE; SERTRALINE; TRAZODONE; TRIMIPRAMINE; VALPROIC ACID; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BIPOLAR DEPRESSION; CLINICAL ARTICLE; DRUG EFFICACY; ELECTROCARDIOGRAM; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; MONOTHERAPY; PERSONALITY DISORDER; PSYCHOMETRY; PSYCHOMOTOR RETARDATION; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; THOUGHT DISORDER; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 84894251759     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: 10.12740/pp/20566     Document Type: Article

References (26)

1. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J. Clin. Psychiatry 2006; 67(supl. 6): 16-22.
2. Fosdick L, Silberman A, Beckman M, Spivak B, Amital D. The economic impact of depression: resistance or severity? Eur. Neuropsychopharmacol. 2010; 20(10): 671-675.
3. Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr. Med. Res. Opin. 2010; 26(10): 2475-2484.
4. Fornaro M, Giosuè P. Current nosology of treatment resistant depression: a controversy resistant to revision. Clin. Pract. Epidemiol. Ment. Health 2010; 6: 20-24.
5. Zarate CA Jr, Du J, Quiroz J, Gray NA, Denicoff KD, Singh J i wsp. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann. N. Y. Acad. Sci. 2003; 1003: 273-291.
6. Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009; 15: 525-539.
7. Permoda-Osip A, Rybakowski J. Koncepcja glutaminergiczna chorób afetywnych. Psychiatr. Pol. 2011; 45(6): 875-888.
8. Gosek P, Chojnacka M, Bieńkowski P, Świecicki Ł. Zastosowanie antagonisty receptorów NMDA (N-metylo-D-asparaginianu) - ketaminy w leczeniu depresji lekoopornej. Psychiatr. Pol. 2012; 46(2): 283-294.
9. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressant: A critical overview. Pharmacol. Rev. 2006; 58: 115-134.
10. Pittenger C, Duman RS. Stress, depression, and neuroplasticity. A convergence of mechanisms. Neuropsychopharmacol. 2008; 33: 88-109.
11. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 2009; 61: 105-123.
12. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci. 2009; 30: 563-569.
13. Pilc A, Wierońska JM, Skolnick P. Glutamate-based antidepressants: preclinical psychopharmacology. Biol. Psychiatry 2013; 73: 1125-1132.
14. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S i wsp. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010; 67(8): 793-802.
15. Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, DiazGranados N, Cravchik A i wsp. Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol. Psychiatry 2012; 71: 939-946.
16. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG i wsp. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011; 35: 1155-1159.
17. Rybakowski JK, Permoda-Osip A, Skibińska M, Adamski R, Bartkowska-Śniatkowska A. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum. Psychopharmacol. 2013; 28(1): 87-90.
18. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA i wsp. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006; 63(8): 856-864.
19. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS i wsp. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000; 47: 351-354.
20. Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B i wsp. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. Neuroimaging 2011; 191: 122-127.
21. aan het Rot M, Zarate CA, Charney D, Mathew SJ. Ketamine for depression: where do we go from here. Biol. Psychiatry 2012; 72: 537-547.
22. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod. Probl. Pharmacopsychiatry 1974; 7: 151-169.
23. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS i wsp. Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J. Trauma. Stress 1998; 11: 125-136.
24. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979; 134: 382-389.
25. Papakostas GI, Fava M. Predictors, moderators and mediators (correlates) of treatment outcome in major depressive disorder. Dialouges Clin. Neurosci. 2008; 10(4): 439-451.
26. Lemche E, Giampietro VP, Brammer MJ, Surguladze SA, Williams SC, Phillips ML. Somatization severity associated with postero-medial complex structures. Sci. Rep. 2013; 3: 103.